Should Interventional Pulmonologists Take Ownership for Ordering Next-Generation Sequencing and Immunohistochemistries for Patients With Newly Diagnosed Non-Small Cell Lung Cancer?

The advent of genetically targeted therapy for metastatic lung cancer provides newfound hope for patients with advanced disease. Next-generation DNA sequencing (NGS) identifies driver oncogenes in tumor cells. Patients found to have actionable genetic alterations (eg, mutations, translocations) treated with genetically targeted therapy may have superior outcomes compared with those receiving traditional platinum-based chemotherapy. For example,...